Small Molecule Drug Development Services
Small molecule drugs make up the vast majority (90%) of all therapeutics options. This category of chemicals involved in Autoimmune Disease & Inflammation has been vigorously developed owing to their high cellular permeability and convenience of administration. Our company provides professional and cutting-edge research services to help you explore the potential of your molecules and accelerate the drug development in Autoimmune Diseases & Inflammation.
Small Molecule Drugs for Autoimmune Diseases & Inflammation
Currently, dysregulated activity of kinases and nucleic acid sensing pathways, as well as cytokines and receptors on the cell surface, is considered to be the main cause of Autoimmune Diseases & Inflammation. Consequently, evolving small molecule drugs have demonstrated different mechanisms for extracellular and intracellular targets, acting as kinase inhibitors, nucleic acid antagonists and inhibitors, as well as targeting cytokines and cytokine receptor complexes, aiming to mitigate the aberrant inflammation. The importance of targeting and accuracy in small molecule drug therapeutics has been underscored, while the effectiveness and long-term safety of existing small molecule therapies still has much room for improvement.
Fig.1 Small molecule disrupts cytokine/cytokine receptor complexes to treat autoimmune and inflammatory diseases (Zheng J., et al., 2021)
Small Molecule Drug Development for Autoimmune Diseases & Inflammation
Small molecule drug development is time-consuming process that comes with intricacies and high risks. With the rapid progress in molecular genetics and cell biology, the probability of efficacy conversion is expected to be greatly enhanced, and the high-tech of biochemistry and medicinal chemistry has also greatly enriched the tools of enhancing efficacy. At present, small molecule drugs account for a considerable proportion of the development pipeline and approved drugs of large pharmaceutical development companies around the world for the therapeutics of Autoimmune Diseases & Inflammation.
Pipelines
LITFUL
- Crohn's Disease
- Ulcerative Colitis
- Vitiligo
Etrasimod
- Atopic Dermatitis
- Crohn's Disease
- Alopecia Areata
- Eosinophilic Esophagitis
SOTYKTU
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Discoid Lupus Erythematosus
Products
RINVOQ™
- Crohn's Disease
- Atopic Dermatitis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
VTAMA®
- Adult Plaque Psoriasis
ZEPOSIA®
- Crohn’s Disease
Fig.2 Developing and developed small molecule drugs for the therapeutics of autoimmune diseases
Our Services
Small molecule drug development is a highly technology-intensive and complex process, involving knowledge from multiple disciplines such as chemistry, biology, pharmacology and so on. Our company provides you with experienced team and necessary resources to produce authentic and reliable experimental results to support the small molecule drugs development for Autoimmune Diseases & Inflammation.
According to preconditions of a proven small molecule drug or a known target protein, the next step should be phenotype-based or target-based approach.
Screening of different types of small molecule drugs targeting a variety of known kinases, receptors, cytokines, or pathways is becoming a hotspot for development.
The design, make, test, analyse (DMTA) cycle is performed iteratively to optimize the chemical properties of the drug without compromising its potency.
In vitro or in vivo animal models are used to test ADMET/PK of drugs. The safety and feasibility of drugs are collected from a diverse series of bioanalysis.
Our Advantages
Full range of innovative program services
Complete set of high-tech equipment
High-level professional technical team
Competitive scientific research strength
With the participation of senior engineers and scientific researchers from a variety of disciplines, and with real success and experience harvested from a large number of projects, our company will help you make comprehensive researches related to small molecule drug development for Autoimmune Diseases & Inflammation. If you are interested in our services, please contact us for more detailed information.
Reference
- Zheng, Jiamin et al. "Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes." Bioorganic & medicinal chemistry letters 48 (2021): 128229.